Results 111 to 120 of about 306 (236)

Connectivity Labeling in Faulty Colored Graphs. [PDF]

open access: yesDistrib Comput
Petruschka A, Sapir S, Tzalik E.
europepmc   +1 more source

Characterization of cell-fate decision landscapes by estimating transcription factor dynamics. [PDF]

open access: yesCell Rep Methods, 2023
Jiménez S   +4 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Robust Material Properties in Epitaxial In<sub>2</sub>Te<sub>3</sub> Thin Films across Varying Thicknesses. [PDF]

open access: yesSmall
Buchta M   +11 more
europepmc   +1 more source

An Efficient Triplex TaqMan Quantitative PCR to Detect a Blackleg-Causing Lineage of Pectobacterium brasiliense in Potato Based on a Pangenome Analysis. [PDF]

open access: yesMicroorganisms, 2023
van der Lee TAJ   +10 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Advances in drug delivery systems, challenges and future directions. [PDF]

open access: yesHeliyon, 2023
Ezike TC   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy